Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 16,149 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Arthritis, Rheumatoid
Interventions: Sirukumab 100 mg, Sirukumab 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 66
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more

Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions: Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Carcinoma
Interventions: Cryotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Urbana, Illinois • Grand Rapids, Michigan • Rochester, Minnesota + 5 more

Conditions: Psoriasis, Cardiovascular Disease
Interventions: Ustekinumab, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastrointestinal Symptoms, Bloating, Digestive Discomfort, Low Energy Levels, Brain Fog, Mood Instability, Sleep Quality, Skin Clarity, Facial Puffiness, Bad Breath
Interventions: Super Liver; Dietary Supplement
Lead sponsor: SuperBonsai Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hyperhidrosis
Interventions: Umeclidinium, Vehicle; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 5
States / cities: Omaha, Nebraska • Raleigh, North Carolina • Austin, Texas + 2 more

Conditions: Breast Cancer
Interventions: Talazoparib, Sacituzumab Govitecan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Staphylococcus Aureus, Community-acquired Infections, Staphylococcal Skin Infections
Interventions: 2% chlorhexidine gluconate (CHG) impregnated cloths, Comfort Bath cloths (placebo cloths); Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 35 Years
Enrollment: 1,563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Quantico, Virginia

Conditions: Alopecia
Interventions: Setipiprant, Placebo, Finasteride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more

Conditions: Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions: Bevacizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Breast Cancer, Lymphedema
Interventions: questionnaire administration, lymphedema management; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System; Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Neoplasms
Interventions: 9 Peptides from Her-2/neu, CEA, & CTA; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Metastatic Breast Cancer, Breast Cancer
Interventions: Pulsed Electric Field (PEF) System, Questionnaires, Tumor Ablation; Device · Behavioral · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatic Impairment
Interventions: Avacopan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Malignant Melanoma Stage IV
Interventions: DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Skin Diseases, Telemedicine, Quality of Life
Interventions: Store and forward teledermatology; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Columbia, Missouri

Conditions: Psoriasis, Obesity, Cardiovascular Risk, Inflammation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 18 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lichen Planus, Oral
Interventions: Hydroxychloroquine; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tinea Pedis
Interventions: 1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C; Drug
Lead sponsor: Propedix, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Framingham, Massachusetts • Milford, Massachusetts

Conditions: Lipedema
Interventions: Quadrivas Therapy; Other
Lead sponsor: University of Arizona; Other
Eligibility: 19 Years to 70 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Metastatic Melanoma
Interventions: Melanoma Reactive TIL, Cyclophosphamide, IL-2, Fludarabine, 1200 total body irradiation (TBI); Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Pulsed Electric Field Ablation for Metastatic Breast Cancer

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Impact of Teledermatology on Health Services Outcomes in the Department of Veterans Affairs

Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study

Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma